learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
1 / 1 resultsResearch
5 / 859 results
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
Community Join
5 / 53 resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community Kintor’s KX-826 Pyrilutamide!!
KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.